NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the launch of a new line of germline cancer predisposition testing services. The new ...

-Collaboration will leverage NeoGenomics’ large oncology diagnostic laboratory and Massive Bio’s proven-at-scale proprietary artificial intelligence platform to accelerate drug discovery and optimize ...

NeoGenomics announced the launch of RaDaR® ST, its circulating tumor DNA assay for detecting molecular residual disease.

Neo Comprehensive™ - Heme Cancers is a large and comprehensive next-generation sequencing panel with broad coverage of genes associated with blood cancers Early-stage NSCLC Panel - a therapy selection ...

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new research at the International Society ...

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and ...

NeoGenomics (NEO) moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026 FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ:NEO), a ...

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q4 CY2025 results exceeding the market’s revenue ...

NEO recently announced the availability of its new pan-solid tumor assay, PanTracer Pro, designed to help clinicians navigate ...